We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Plethora | PLE | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 3.375 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 3.375 | 3.375 |
| Top Posts |
|---|
Posted at 30/1/2018 11:56 by the grumpy old men Koninklijke Philips NV (PHIA.AE) said Tuesday that net profit decreased 26% in the fourth quarter, as it backed its 2018 guidance and kept its dividend unchanged.The Dutch electronics producer said that net profit was 476 million euro ($590 million) in the last three months of 2017, compared with EUR640 million the year before. Comparable sales were up 5% on the back of its personal-health division as well as its diagnosis and treatment businesses. Philips said it increased its adjusted earnings before interest, tax, and appreciation margin by 140 basis points to 16.7%. The company kept its dividend unchanged form last year at 80 cents. Chief Executive Frans van Houten backed the company's targets for 2018, and said he was confident in delivering 4%-6% comparable sales growth and on average 100 basis points annual improvement in adjusted Ebita margin this year. "We expect our markets to grow at 3%-5% on a comparable basis in 2018," he added. The company said it had reduced its shareholding in Philips Lighting down to 29% as of Dec. 31. Philips said that it was delivering on its productivity program ahead of schedule, with annual savings of EUR483 million, ahead of its EUR400 million target. Write to Carlo Martuscelli at carlo.martuscelli@do (END) Dow Jones Newswires January 30, 2018 01:46 ET (06:46 GMT) |
Posted at 22/2/2016 11:40 by knicol46 SP up 8%. from scheme document..The increase in the pro forma net assets of the Enlarged Group is mainly due to the fact that at the acquisition date there will be a recognition of the fair value of the PSD502 patent (intangible asset) net of deferred taxation of US$171.9 million. Based on the Closing Price of HK$0.069 of a Share on 29 January 2016 and 14,047,113,239 Consideration Shares being issued in connection with the Transaction, the Enlarged Group would have an assumed combined market capitalisation of approximately HK$1,209.77 million. On the basis of the Closing Price of a Share of HK$0.069 on 29 January 2016, the Transaction represents an indicative value for each Plethora Share of 9.81 pence, values the entire issued ordinary share capital of Plethora at approximately £80.8 million and values the fully diluted share capital of Plethora at approximately £97.5 million. As of 22 February 2016 the current share price of PLE is 3p – giving a market value of £24m As of 22 February 2016 the current share price of RP is HK$0.073 * 15.7076 = HK$1.14 = 10.36p PLE equivalent value |
Posted at 17/2/2016 18:57 by mortimer7 I thought it may be helpful to share some extracts from information received from a share dealing service I use (Halifax):-"The Acquisition, based on the Closing Price of a Regent Pacific share of HKD0.069 (equivalent to 0.6 pence) on 29 Jan 2016 (being the last practicable date prior to the publication of the Scheme Document), represents an indicative value for each Plethora share of 9.81 pence per share, valuing the fully diluted share capital of Plethora at approximately GBP96.27 million. The Acquisition, at the indicative value of 9.81p per Plethora share represents an indicative premium of approximately 241.3% to the Closing PLE Price of 2.875p on 29 Jan. Please be aware that the New Regent Pacific shares will be admitted to trading on the Hong Kong Stock Exchange; as a result we will be unable to facilitate trading in the Regent Pacific shares via our sharedealing facility. Regent Pacific also maintain a listing of the shares on the Wertpapierboerse of the Frankfurt Stock Exchange. As such, upon receipt of the shares, we will endeavour to transfer them to the Frankfurt Stock Exchange in order to facilitate trading. Trading on this market will, however, be limited to sell only transactions" |
Posted at 11/11/2015 14:17 by big_cat This is from Simon Thompson in Investors Chronicle this morning ....Plethora gets a boost The other news that caught my eye was the bid approach from Hong Kong-listed Regent Pacific (Hong Kong Stock Code: 575), the investment vehicle of Jim Mellon, for Aim-traded Plethora Solutions (PLE: 5p), a UK-based speciality pharmaceutical company dedicated to the development and marketing of products for the treatment and management of urological disorders. Plethora's principal product is PSD502™, a prescription treatment for male premature ejaculation that obtained marketing authorisation from the European Commission in November 2013. Regent Pacific and its concert parties together already hold 29.88 per cent of Plethora's issued ordinary share capital and their indicative offer has been pitched at 15.7076 new Regent Pacific shares for each Plethora share. On the basis of Regent Pacific’s share price of HK$0.10, and using a sterling to Hong dollar exchange rate of £1:HK$11.71, the potential offer values each Plethora share at 13.4p, the company’s issued ordinary share capital at £110m and fully diluted share capital (excluding the out-of-money outstanding options and warrants) at £131m. This represents a thumping premium to Plethora’s sagging share price of 2.75p prior to news of the offer being made. But before you get too excited it’s worth flagging up that there is no cash element and Regent Pacific only has a market value of £30m. That’s less than Plethora’s market value of £41m and explains why there is such a big difference between the implied offer price of 13.4p a share and Plethora’s current share price of 5p. Still it’s fair to assume that a formal bid will be made as Regent Pacific has since received letters of intent from investors controlling 10.96 per cent of the Plethora’s issued share capital, so now has almost 41 per cent of the equity backing the bid. Clearly, it’s not going to be possible for everyone to buy Plethora’s shares in the London market at 5p, sit back and wait for the formal bid to be made, and then sell your Regent Pacific shares immediately at 13.4p in Hong Kong. If every investor attempts to do this then Regent Pacific’s share price will fall sharply given that it is issuing 15.4bn shares or more than four times its current issued share capital. That said, one of the reasons Plethora’s shares were so weak in the first place was down to the fact that the company is short of funds, so the price has been depressed due to financial distress. Eliminate this factor and a higher valuation is warranted. Prospects for PSD502™ Indeed, Plethora only has cash balances of £1m, and guidance is that commercial operations under its current operating plans will face a “significant negative impact in January 2016 in the absence of further funding being available to Plethora.” Regent Pacific has net cash and unpledged listed equity securities worth about £8.9m on its balance sheet which it can use in order to develop and commercialise PSD502™, and meet the substantial funding needs of Plethora in the near future. Moreover, it is desirable to progress with planned expenditure in key areas which support the development and commercialisation of PSD502™, such as manufacturing of a reduced fill can for the product, and research and development spend associated with a New Drug Application approval with the US regulator. A key objective is to obtain EU approval by 30 June 2016 for its reduced fill product, such that Plethora can obtain the variation payment of €6m from its European licence partner Recordati (REC:MIL), a €4.8bn pharmaceutical group listed on the Milan Stock Exchange, in preparation for its commercial launch in the EU; and firming up licenses for other territories too. Plethora’s board has had discussions with partners in Latin America, Asia Pacific and South Africa, and with a multi-national pharmaceutical company for 'out licensing' the grant of rights by Plethora in respect of PSD502™ for countries in the Middle East. In all cases the parties have entered into non-binding heads of terms and have moved into discussions on the licence agreement which anticipate an up-front payment to Plethora followed by additional payments upon the achievement of certain milestones plus royalties linked to sales. However, before negotiations can complete a reduced fill product for PSD502™has to be developed and manufactured under good manufacture practice conditions. And for that Plethora needs more funding. This is where Regent Pacific comes in. Implied value of Plethora Clearly, Mr Mellon and his concert party can see great potential in PSD502™otherwi Furthermore, it’s worth noting that Plethora self-developed this product and had not capitalised any of the costs incurred, nor any of the future value it may derive. Regent Pacific, with the assistance of a professional independent valuation expert, Jones Lang LaSalle Corporate Appraisal and Advisory, determined the fair value of PSD502™ based on the “relief from royalty method” to be in the region of US$253m, or £167m at current exchange rates. This explains why Regent Pacific’s indicative offer values Plethora’s equity north of £100m. Only time will tell whether this is a fair valuation or not. Frankly, whether or not PSD502™ is a success is not the issue here. I am far more concerned as to what will happen to Regent Pacific’s share price if it launches a formal bid and Plethora shareholders are then issued with a slug of equity. Realistically I can see the price in Hong Kong soften, but certainly not deflate by 60 per cent which is the implied discount in Plethora’s share price. In fact, I reckon that if Regent Pacific launches a bid there could be upwards of 50 per cent upside to Plethora’s current share price of 5p. The interest of Hong Kong investors is being aroused by the potential acquisition too which explains why Regent Pacific’s share price has perked up since news of its bid approach emerged. At around the 5p level, Plethora shares are worth having a small interest in. Speculative buy. |
Posted at 11/11/2015 10:02 by tsmith2 Plethora (PLE) was a company that I was only vaguely aware of up until last week when a potential takeover bid was made for it. Up until then this AIM-listed pharmaceutical company, whose main product is a premature ejaculation treatment, had been trading at between 3p and 4 p, but then an offer landed from Hong Kong investment vehicle, Regent Pacific (also listed in Frankfurt but volume there is almost non-existent), that valued Plethora at 12.5p per share.The offer wasn’t quite as random as it might first have appeared as the two companies have close links, and Jim Mellon and his Regent Pacific vehicle, plus other interests he has, own just under 30% of Plethora. The share price rocketed to over 7p on the day of this news, but has since dropped back to the current level of around 5p. That might seem strange until you look at the deal in more detail and see that it is an all-paper offer, with Plethora holders getting 15.7076 Regent shares for every share that they hold. That made it far less certain that the deal will ultimately be worth 12.5p, if and when it is finalised, and many private investors didn’t seem too keen on possibly ending up with Hong Kong listed stock and sold into the spike. Since then we have seen a continued sell-off of Plethora shares – probably partly from people who bought near the top of the spike and then sold because it didn’t hit 12.5p overnight! – and that has included one of the institutional holders, Baker Brothers, selling a small amount of its holding. What we haven’t seen though, and which has surprised me, is any sort of sell off of Regent shares in Hong Kong, where the share price has remained steady at around HK0.1. This suggests to me that Regent investors are keen on the deal and see it as offering value. Currently Regent has cash but is looking for an investment to generate revenue, and Plethora has a finished product but is desperately short of money. Both share prices are at their lowest levels for sometime and have been a lot higher in recent times, so it could be that the market is viewing the combined entity as likely to be far stronger than the sum of the two separate parts. For me this is all about the potential opportunity being offered by the low Plethora price if the deal goes ahead as planned, and I have been buying at just over 5p on that basis – having watched the reaction in Hong Kong before taking a position. I would expect that those who don’t want to end up with Hong Kong listed shares will sell out before any deal is done, but it is also likely that we will see selling pressure on Regent after the deal due to the huge number of new shares issued. Although there are relatively few Plethora shares are in freefloat and a lot of the outstanding warrants won’t come into play – a chunk of those are owned by parties related to Jim Mellon and Regent so can’t be exercised during a bid period, and the ones from the last placing are at 15p so aren’t currently relevant – so we may not see as much of a sell-off of Regent shares as some might be expecting. The Regent price would also have to collapse to around HK0.04 as well to make it equivalent to the current Plethora price of 5p! Should the deal be finalised and go to a vote it should be a formality that it goes through, as the board has recommended it be accepted and Regent has already received a letter of intent from two big holders pledging support through voting rights on over 10% of the shares in issue. There is of course some risk that this could go lower, but from the current level I personally see good risk versus return, whether you are in for a trade or holding until after the deal is done. - See more at: hxxp://www.shareprop |
Posted at 10/11/2015 15:55 by zangdook I wouldn't assume that PLE share price is "right" and 575 share price is "wrong" and will adjust. The PLE price has been adjusting and will probably continue to do so.Of course, after the merger goes through old PLE holders will make up ~80% of the share register and some of them will be holding on now intending to dump in HK - see Cawkwell - so there may be a correction. But if HK holders of 575 thought there would be a correction downwards they would sell now and buy back later, and through that selling pressure the correction would be brought forward. The low volumes in HK show that there is not selling pressure being absorbed by friends of Jim Mellon in order to keep the share price steady as was suggested above. People are not dumping the stock. In fact there has already been a fairly substantial move upwards in the PLE share price It's met selling pressure from profit-takers, stale bulls, people who don't like the takeover, people who don't want to hold HK stock etc. I would expect a further move up here as the deal becomes more certain and as the sellers sell out. That's just a guess though, I can't predict. |
Posted at 10/11/2015 08:37 by liquid millionaire Regent Pacific Group LimitedPossible Offer for Plethora Solutions Holdings plc Letter of Intent received from each of Forest Nominees Limited and W B Nominees Limited Further to the announcement on 4 November 2015 (the "Announcement") in relation to the possible offer (the "Possible Offer") for Plethora Solutions Holdings plc ("Plethora", AIM: PLE) by Regent Pacific Group Limited ("Regent", Hong Kong Stock Code: 0575), Regent is pleased to announce that it has received a letter of intent from Forest Nominees Limited ("Forest Nominees") in relation to 76,357,880 ordinary shares in the capital of Plethora and a letter of intent from W B Nominees Limited ("W B Nominees") in relation to 13,848,458 ordinary shares in the capital of Plethora, together representing approximately 10.96 per cent. of the current issued ordinary share capital of Plethora. Each of Forest Nominees and W B Nominees has confirmed that, if a firm offer announcement is made, it is their current intention to cast, or procure the casting of, all votes (whether on a show of hands or a poll and whether in person or by proxy) in respect of the ordinary shares in Plethora they currently hold and any other ordinary shares in Plethora of which they may hereafter become the registered owner, beneficial owner or in which they may become interested at any court meeting, general meeting or class meeting in connection with the Possible Offer to enable the Possible Offer to become effective. Forest Nominees and W B Nominees have each provided their letters of intent on the basis of the terms of the Possible Offer (including the exchange ratio) set out in the Announcement. The letters of intent from Forest Nominees and W B Nominees are the first letters of intent received by Regent to date in relation to the Possible Offer. Capitalised terms used in this announcement have the meaning given to them in the Announcement. Information on Regent The board of directors of Regent consists of James Mellon (Non-Executive Co-Chairman), Stephen Dattels (Non-Executive Co-Chairman), Jamie Gibson (Executive Director and Chief Executive Officer), David Comba (Independent Non-Executive Director), Julie Oates (Independent Non-Executive Director), Mark Searle (Independent Non-Executive Director) and Jayne Sutcliffe (Non-Executive Director). |
Posted at 06/11/2015 19:51 by tsmith2 had slightly decided not to say anything about Plethora (PLE) and the bid since the chairman owns 29% of PLE and is the controlling luminary at Regent Pacific, whose number on the HKSE is 575. This modesty was partly occasioned by my ignorance but principally because the chairman also controls this site.However, I can restrain myself no further. On Day 1 of the possible bid, Wednesday, I paid 7p for PLE since, ostensibly, the offer was worth 12.5p. However, the offer is only in RP paper whose value I could not then check since HK was closed. I therefore resigned myself to a sharp sell-off of RP when HK reopened yesterday morning (c. 1.30 a.m. London time). You may therefore imagine my surprise when I checked the HK closing price yesterday morning. It was unchanged from Tuesday night and volume was about 35m shares. Given that the offer is 15.7 RP shares for each PLE share, that is the equivalent of 12.5p, I therefore decided that the RP price is real and not a fake.So I checked RP's HK price at the close first thing this morning and it still stands at 0.097 or put another way the equivalent of c. 12.5p. Volume in HK last night was only 6m but even so it smells real enough to me. So I again bought PLE this morning this time at 5p.Realistically, we have seen this discount before. Some may remember London-quoted issues going east a few years back and the discount was colossal of the order of 40%. The wise guys said "You'll learn". Fortunately I did not learn since I went on to sell the former London counters in HK at the full price.So what was and is going on? I'm afraid to say that UK retail investors are just being silly and selling out in London whereas it is perfectly possible to sell London-acquired PLE as HK-quoted RP. All that is required is a little patience and persistence.And the chairman? He has been as far as I am concerned on this subject as quiet as a mouse. But I know he hopes that RP will emerge as a serious "drug firm". Make of that what you will. He is certainly serious. |
Posted at 06/11/2015 10:45 by papy02 OK, let's assume Regent Pacific shareprice remains flat through to after the deal is consumated, at a level that's worth 12.5p/share to Plethora holders.Before the possible offer was announced we have: Plethora mkt cap (at share price of 2.75p): £23m Regent Pacific mkt cap (at share price of .093 HK$): £28m Total mkt cap of the 2 companies before announcement: £51m After (/if) the offer is consumated we have: Regent Pacific mkt cap (at flat share price of .093 HK$): £139m, after 13.9bn RP shares issued to PLE holders - I assumed RP holding in PLE doesn't change prior to the consumation (from the 86.8m shown on PLE website). So the "merger" will have produced additional value of £88m, and a mkt cap 2.7 times that of the total of the 2 companies before the offer was announced. All the benefit goes to PLE holders (under the assumption that the Regent share price is unchanged). Presumably Regent shareholders would want to see some upside to wave this through, requiring value-creation on an even more heroic scale. This spectacular increase in value will be created by providing the finance to bring Fortacin to market, via this "merger"? (as opposed to PLE finding funding for this elsewhere). Doesn't stack up for me, unless PLE would not have been able to get funding elsewhere, and that was in the share price (in which case, why?). (Regent increasing its share of PLE prior to deal consumation could reduce the new Regent shares issued and additional mkt cap numbers a bit, but not enough to change my conclusion). The above analysis led me to dump PLE on Weds after buying in on the RNS. For a 20% loss :-( If any of the numbers or reasoning are wrong, I would appreciate being educated. |
Posted at 05/11/2015 22:19 by smithie6 Gotab..imho ...dont base your views on the small rise of share price of Regent ( ..imho...need to try analyse the offer and your part of PLE now & compare with your part of a merged entity & compare pros & cons etc of both.....& if desired seek prof. advice ( !!) NAG. DYOR. With merger or offer news ( & company results or RNS) it is common to see a share price move....news creates viewers and interest...which can lead to buyers... A jump in interest and small price rise in Regent doesnt mean imo that the merger is good for holders of Regent.... or PLE at a specific share price. ( although PLE doubling in price shows imo that mkt thinks its good for PLE....imho...I assume since it hopefully would provide the cash that PLE appears to need) Im not a PLE expert....pharma/med --- Zzz ( snoozebox jumped maybe 50% 1-2 years ago....partly since tipped by Paul Scott.....it then halved in price over later months..) ... My website opened 2 paper shorts on Vislink on rise in price ....closed today (tweeted)...1 went from 60p to 38.2p :-)....and tweeted website short in Fitbug from 18.5p now 2p ! ( & opened 2nd short. 9p).......proof that a rise in price is no gtee that a price will keep going up ! PLE.. Im not saying its a good or bad deal at 15 new shares....just trying to explain a point.. ----- Anyway...the offer has been good for PLE holders over recent days...with jump in value of shares... @fulltimeinvest |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
